UK healthcare equities saw a welcome rebound in 2025, but the story behind the numbers is far more complex. In this Hardman Talks, CEO Keith Hiscock is joined by Dr Martin Hall, Head of Life Sciences at Hardman & Co, to explore the forces shaping the UK healthcare sector. From shrinking institutional support and funding challenges for small cap companies to the hurdles of commercialising approved technologies, Martin provides a frank, data-driven assessment of the market and its future prospects.
Drawing on recent case studies and decades of experience, Martin also reflects on the unpredictable factors that can make or break healthcare investments. Whether you’re an investor, industry professional or simply interested in the future of UK life sciences, this interview offers insight, context and an honest look at what 2025 revealed – and what it might mean for 2026.
Watch the full discussion to understand why recovery alone may not be enough to secure the sector’s long-term success.
Read Martin’s latest Hardman & Co Healthcare Index for more detail.
